Nanostrategies in the war against multidrug resistance in
leukemia
Review
Article
AUTHORS: Alphy Rose-James1, TT
Sreelekha1, Suraj K. George2*
AFFILIATIONS: 1Laboratory of
Biopharmaceuticals, Division of Cancer Research, Regional Cancer Centre,
Thiruvananthapuram-695 011, Kerala, India.
2Dept.
of Hematopathology, Division of Pathology and Laboratory Medicine, University
of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas
77030, USA
Chemotherapy is the cornerstone of treatment for
haematological malignancies. Despite innovative advances in the understanding
of this complex disease, multidrug resistance (MDR) is still a major culprit
for the treatment failure, especially in leukemia. Conventional combinatorial
therapy is a major decoy to circumvent MDR, but those are frequently thwarted
by the evolving intricacies of the cancer paradigm. The advent of nanomedicine
has ushered a new era with striking pharmacokinetic drug properties far enough
to combat MDR. Physicochemical elements such as co-encapsulation, drug influx,
ratiometric drug loading, temporal sequencing on drug release, and selective
targeting moiety have been better tailored within the nanotherapeutics to
overcome MDR. This review focuses on a plethora of nanostrategies and
nanoplatforms which have been developed so far to battle MDR in leukemia.
Download f
ull text
(PDF) from OncoDrugs
